Add-on Sodium Benzoate and N-Acetylcysteine in patients with early schizophrenia spectrum disorder: a multicentre, double-blind, randomised placebo controlled feasibility trial

Abstract

Oxidative stress pathways may play a role in schizophrenia through direct neuropathic actions, microglial activation, inflammation, and by interfering with NMDA neurotransmission. N-acetylcysteine (NAC) has been shown to improve negative symptoms of schizophrenia, however, results from trials of other compounds targeting NMDA neurotransmission have been mixed. This may reflect poor target engagement but also that risk mechanisms act in parallel. Sodium Benzoate (NaB) could have an additive with NAC to act on several pathophysiological mechanisms implicated in schizophrenia. A multicentre, twelve-week, 2x2 factorial design, randomized double-blind placebo-controlled feasibility trial of NaB and NAC added to standard treatment in 68 adults with early schizophrenia. Primary feasibility outcomes included recruitment, retention, completion of assessments as well as acceptability of the study interventions. Psychosis symptoms, functioning and cognitive assessments were also assessed. We recruited our desired sample (n=68) and retained 78% (n=53) at 12-weeks, supporting the feasibility of recruitment and retention. There were no difficulties in completing clinical outcome schedules. Medications were well tolerated with no dropouts due to side effects. This study was not powered to detect clinical effect and as expected no main effects were found on the majority of clinical outcomes. We demonstrated feasibility of conducting a clinical trial of NaB and NAC. Given the preliminary nature of this study, we cannot draw firm conclusions about the clinical efficacy of either agent and a large scale trial is needed to examine if significant differences between treatment groups emerge.